GLP-1 & compounded medication availability in North Dakota (2026)
North Dakota formalized its expectations for out-of-state pharmacies in 1988, decades before telehealth made a mailed prescription ordinary, and the permit rule it wrote then is still the operative fact for an order shipped into the state today. Nothing North Dakota-specific singles out any of the ten lines on this page: eight ship, two do not, and both of those gaps are ours, not the state’s.
The ten-line matrix for North Dakota
| Product line | Available in North Dakota? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Shipped by permit-holding partner pharmacies. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Flat national pricing, no state surcharge. |
| NAD+ | Yes | 8–10 business days | Ordered via the standard telehealth evaluation. |
| Sermorelin | Yes | 8–10 business days | Dispensed by out-of-state partner pharmacies with board permits. |
| Glutathione | No | N/A | Not yet in the OrderlyMeds formulary anywhere. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; cited federal facts below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; its record is cited below. |
| KPV | No | N/A | Not part of our catalog in any state; injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; the section below carries its citations. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its federal record stands apart, below. |
Last reviewed November 16, 2026. Two No rows are catalog gaps on our side. North Dakota itself draws no line around any product on this page.
Research peptides and North Dakota: the plain answer
The North Dakota answer is the national answer. OrderlyMeds dispenses BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables on patient-specific prescriptions, in North Dakota as everywhere; KPV is in the formulary nowhere, because it is not an injectable line. Each section below states the cited federal record for its one substance, FDA’s safety position and the current compounding pathway, and the records are given separately because they are not interchangeable.
BPC-157 in North Dakota
North Dakota orders for BPC-157 are filled as a compounded injectable, on a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in North Dakota
TB-500 is dispensed to North Dakota addresses as a compounded injectable.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in North Dakota
KPV is not something OrderlyMeds dispenses, in North Dakota or any state, because it is not compounded as an injectable and injectables are what our peptide lines are.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in North Dakota
Epitalon ships to North Dakota as a compounded injectable, on a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in North Dakota
MOTS-c is dispensed to North Dakota as a compounded injectable; its federal record below is specific to it.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What North Dakota’s pharmacy regulators say about compounded medications
North Dakota’s defining trait here is how early and how concretely it answered the mail-order question. Administrative rules effective April 1, 1988 require any pharmacy outside the state shipping dispensed prescription drugs to North Dakota residents to hold the board’s own permit, a requirement written when mail-order pharmacy was novel and renewed annually ever since. Its telemedicine rules are similarly concrete: the initial exam may happen entirely by video, with prescribing authority following from it.
North Dakota regulates pharmacy practice and compounding through board permits and rules under N.D.C.C. ch. 43-15; no GLP-1-specific or peptide-specific restriction has been published. Source: N.D.C.C. ch. 43-15 — Pharmacists.
Any pharmacy operating outside North Dakota which ships, mails, or delivers a dispensed prescription drug into the state must obtain and hold a pharmacy permit issued by the North Dakota State Board of Pharmacy, renewed annually by July 1 (N.D. Admin. Code 61-08-01-01, effective April 1, 1988). Source: N.D. Admin. Code ch. 61-08-01 — Out-of-State Pharmacies.
North Dakota permits an examination or evaluation to be performed entirely through telemedicine where it is equivalent to an in-person examination, and a licensee who has performed one may prescribe non-controlled medications in their professional judgment (N.D.C.C. §43-17-44.1). Source: N.D.C.C. ch. 43-17 — Physicians (§43-17-44.1).
So a Fargo or Bismarck order follows a path North Dakota mapped long ago: a telehealth evaluation with a provider authorized for the state, a patient-specific prescription, fulfillment by a partner pharmacy holding the board’s out-of-state permit, and tracked delivery inside the published 8–10 business-day window, at the same national price as every other state.
North Dakota availability FAQs
Is compounded semaglutide available in North Dakota?
Yes. Both compounded GLP-1 lines, semaglutide and tirzepatide, ship to North Dakota addresses, from $74/month for new semaglutide customers.
Does North Dakota have extra requirements for mail-order prescriptions?
The requirement sits on the pharmacy, not on you: an out-of-state pharmacy shipping into North Dakota holds a board permit, a rule in place since 1988. The regulator section above cites it.
Which of the five research peptides ship to North Dakota?
BPC-157, TB-500, Epitalon and MOTS-c do, each as a compounded injectable on a patient-specific prescription. KPV does not, in any state. The cited federal record for each sits in its section above.
How long does shipping to North Dakota take?
The published window is 8–10 business days from signup, with tracking throughout.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
